Trial Profile
Phase II Study of Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non Hodgkin's Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Sep 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 30 Aug 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 30 Aug 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.
- 28 Nov 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.